Pharma BD Deal Intelligence
Merck's $620M genomics bet was wound down within a decade — Seattle site shuttered, software unit sold off piecemeal to Microsoft, no drug discovery breakthrough ever publicly attributed to the platform.
Full analysis, sources & comparables →CNN Money reported the all-stock $620M Merck acquisition of Rosetta at $18/share (0.2352 Merck shares per Rosetta share), an 82% premium framed as a strategic…
Nature Biotechnology coverage 'Merck buys Rosetta' framed the transaction as a flagship pharma move into informational genomics and microarray-driven target…
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
All-stock; 0.2352 Merck shares per Rosetta share ($18/share). Original announce value ~$620M, net equity ~$540M. Genomics/microarray informatics platform.
Merck's $620M genomics bet was wound down within a decade — Seattle site shuttered, software unit sold off piecemeal to Microsoft, no drug discovery breakthrough ever publicly attributed to the platform.
Assessment window: 15yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Merck & Co. Inc. / Rosetta Inpharmatics Inc. (this deal) | 2001 | $540M | 25 |
| Merck & Co. Inc. / Acceleron Pharma Inc. | 2021 | $11.5B | 90 |
| Merck & Co. Inc. / Peloton Therapeutics Inc. | 2019 | $2.2B | 88 |
| Merck & Co. Inc. / AstraZeneca PLC | 2017 | $8.5B | 87 |
| Merck & Co. Inc. / Moderna, Inc. | 2022 | $250M | 86 |
| Merck & Co. Inc. / Moderna, Inc. | 2016 | $250M | 84 |
| Merck & Co. Inc. / Eisai Co., Ltd. | 2018 | $5.8B | 83 |
← Browse all deals · How we score deals
More: 2001 deals · Merck & Co. Inc. deals